Syngene International Q2: Profit Falls 52%, So Why Is The Stock Rising? | Business News | ET Now
ET Now · 28 Oct 2026 · 9 min
Management interview of Syngene International Ltd (SYNGENE), with 5 key numbers discussed.
- Sibaji Biswas, MD & CEO, Syngene International
Syngene International reported sequential revenue growth of 13% in Q2, primarily driven by the CDMO business, despite an 8% year-on-year decline caused by the absence of Librela sales and degrowth in Discovery Services. The company expects a stronger performance in H2 compared to H1 due to customer obligations and pipeline conversions. Syngene signed its first contract for the Bayview biologics facility, with initial development in Bangalore before tech transfer next fiscal year. Management maintained its FY27 EBITDA margin guidance in the mid-20s, citing cost optimization and tapering forex hedge losses.